主观认知衰退中的大脑拓变化和与粉状细胞阶段的关联
Xueyan Jiang1,2, Mingkai Zhang3, Chuyao Yan4
1State Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Sanya 572022, China.
概括
粉样蛋白负担影响主观认知衰退 (SCD) 的个体的大脑网络变化,这是阿尔茨海默病 (AD) 的前体. 大脑网络效率的这些变化与粉样蛋白沉积有关,特别是在默认模式的网络枢纽中.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 神经学 神经学
背景情况:
- 主观认知衰退 (SCD) 是阿尔茨海默病 (AD) 的风险状况.
- 粉样蛋白负担是AD的关键病理标志.
- 了解SCD早期的大脑变化对于AD预防至关重要.
研究的目的:
- 为了研究粉样蛋白负担和SCD患者的大脑网络拓学的关系.
- 为了比较SCD和正常对照 (NC) 个体之间的大脑网络特性.
- 探索粉样沉积如何影响AD早期的功能和结构性大脑网络.
主要方法:
- 休息状态功能性MRI和扩散张力成像被用来分析功能和结构性大脑网络.
- 粉样蛋白PET成像和基于频率的分期方法评估了SCD参与者的粉样蛋白负担.
- 大脑网络的拓性质被评估为信息交换效率和稳定性.
主要成果:
- 与NC相比,患有SCD的个体在特定的大脑区域 (左前环和中环环回路) 显示出功能节点效率和结构节点间隔性增加.
- 粉样蛋白负担与所有粉样蛋白阶段的默认模式网络 (DMN) 中枢的节点级属性具有积极的关联.
- 粉样蛋白沉积影响了DMN枢纽,而不考虑接近病理,这表明网络的持续适应.
结论:
- 粉样蛋白负担持续影响大脑网络适应通过DMN枢纽在个人的风险为AD.
- 在皮质枢纽中增加的节点特性可能表明在早期粉样蛋白沉积过程中信息处理需求增加.
- 这些发现突出了网络改变在阿尔茨海默氏症早期病理生理学中的作用.
更多相关视频
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.2K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.7K
相关概念视频
01:26Alzheimer's Disease: Overview
689
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
689
01:30Cognitive Development During Adulthood
317
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
317
01:30Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182
01:13Amnesia
201
Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
201
01:22Alzheimer's Disease: Treatment
266
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
266